Welcome to: Rimonabant Information Source (rimonabant and caffiene)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Acomplia weight loss drug rimonabant is an oral prescription medication which was approved in the United Kingdom only if suppressed appetite and still waiting for approval from the FDA in the U.S.. The works of acomplia diet pill rimonabant is easy to loose weight and appetite. It works based on the simple principle of stimulating the hypothalamus gland, which affect specific neuro-transmitters which are responsible for the intake of food in the body as well as fat. When these neuro-transmitters are aimed caused condensed suppresses appetite or appetite. This means that you eat less than your normal appetite, because you always feel fullness, which in turn would lead to a reduction in weight. To maximize the results of Acomplia diet pills, with an appropriate fitness program and proper diet plan or a balanced diet plan.

Rimonabant Pricelist

Please wait while we load the price list
A new class of weight-loss drugs that suppresses appetite by blocking cannabinoid receptors in the brain should be used with caution in children, U. S.scientists report. In research with mice, they found this class of drugs also suppresses the adaptive rewiring of the brain necessary for neural development in young animals. The findings are in the May 8 issue of Neuron. One such drug is rimonabant (Acomplia), which was developed by Sanofi-Aventis and is awaiting approval by the U. S. Food and Drug Administration. Other pharmaceutical companies are developing similar drugs. Related Results Cheyenne, Wyo.-area doctors skeptical of 'super bill' for weight loss, smoking.

Two-thirds of the patients completed the 1-year trial. The three groups were similar at baseline, with a mean age of 56 years, hemoglobin [A.sub. 1c] of 7. 5%, BMI of 34, and waist circumference of 110 cm. About 60% had hypertension, 55% had dyslipidemia, and 80% met criteria for metabolic syndrome. About two-thirds were taking metformin; one-third were taking sulfonylureas. They stayed on those drugs during the study. In the intent-to-treat analysis of the original 1,045 patients with the last observation carried forward, those randomized to 20 mg/day of rimonabant lost a mean of 5. 3 kg, compared with 1. 4 kg in the placebo group, a highly significant difference.